ATE398125T1 - Chinazolin-derivate als tgf-beta-inhibitoren - Google Patents

Chinazolin-derivate als tgf-beta-inhibitoren

Info

Publication number
ATE398125T1
ATE398125T1 AT04718542T AT04718542T ATE398125T1 AT E398125 T1 ATE398125 T1 AT E398125T1 AT 04718542 T AT04718542 T AT 04718542T AT 04718542 T AT04718542 T AT 04718542T AT E398125 T1 ATE398125 T1 AT E398125T1
Authority
AT
Austria
Prior art keywords
tgf beta
quinazoline derivatives
beta inhibitors
mediated disease
tgf
Prior art date
Application number
AT04718542T
Other languages
English (en)
Inventor
Robert Scarborough
Anjali Pandey
Meenakshi Venkatraman
Original Assignee
Millennium Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32990876&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE398125(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Millennium Pharm Inc filed Critical Millennium Pharm Inc
Application granted granted Critical
Publication of ATE398125T1 publication Critical patent/ATE398125T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT04718542T 2003-03-12 2004-03-08 Chinazolin-derivate als tgf-beta-inhibitoren ATE398125T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US45416403P 2003-03-12 2003-03-12

Publications (1)

Publication Number Publication Date
ATE398125T1 true ATE398125T1 (de) 2008-07-15

Family

ID=32990876

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04718542T ATE398125T1 (de) 2003-03-12 2004-03-08 Chinazolin-derivate als tgf-beta-inhibitoren

Country Status (6)

Country Link
US (2) US7189733B2 (de)
EP (1) EP1603908B1 (de)
AT (1) ATE398125T1 (de)
DE (1) DE602004014347D1 (de)
ES (1) ES2305744T3 (de)
WO (1) WO2004081009A1 (de)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY27224A1 (es) * 2001-03-23 2002-10-31 Bayer Corp Inhibidores de la rho-quinasa
PE20020958A1 (es) * 2001-03-23 2002-11-14 Bayer Corp Inhibidores de la rho-quinasa
CL2004000409A1 (es) * 2003-03-03 2005-01-07 Vertex Pharma Compuestos derivados de 2-(cilo sustituido)-1-(amino u oxi sustituido)-quinazolina, inhibidores de canales ionicos de sodio y calcio dependientes de voltaje; composicion farmaceutica; y uso del compuesto en el tratamiento de dolor agudo, cronico, neu
JP4895806B2 (ja) * 2003-04-09 2012-03-14 エクセリクシス， インク． Ｔｉｅ−２モジュレータと使用方法
US8283354B2 (en) * 2004-09-02 2012-10-09 Vertex Pharmaceuticals Incorporated Quinazolines useful as modulators of ion channels
US7718658B2 (en) * 2004-09-02 2010-05-18 Vertex Pharmaceuticals Incorporated Quinazolines useful as modulators of ion channels
US7928107B2 (en) * 2004-09-02 2011-04-19 Vertex Pharmaceuticals Incorporated Quinazolines useful as modulators of ion channels
ATE549314T1 (de) * 2004-12-17 2012-03-15 Vertex Pharma Verfahren zur herstellung von 4-aminochinazolinen
EP1891039A1 (de) 2005-05-20 2008-02-27 Vertex Pharmaceuticals Incorporated Chinolinderivate als modulatoren von ionenkanälen
EP2079739A2 (de) 2006-10-04 2009-07-22 Pfizer Products Inc. Pyrido[4,3-d]pyrimidin-4(3h)-onderivate als kalziumrezeptorantagonisten
AR070127A1 (es) * 2008-01-11 2010-03-17 Novartis Ag Pirrolo - pirimidinas y pirrolo -piridinas
WO2009146301A1 (en) * 2008-05-27 2009-12-03 Yale University TARGETING TGF-β AS A THERAPY FOR ALZHEIMER'S DISEASE
US20100087486A1 (en) * 2008-05-30 2010-04-08 Hiroshi Nakamura Methods for using tgf-b receptor inhibitors or activin-like kinase (alk) 5 inhibitors a-83-01 and sb-431542 to treat eye disease and wound healing conditions
CN102695511A (zh) * 2009-04-17 2012-09-26 舒玛健康系统有限责任公司 抑制眼部瘢痕形成的转化生长因子-β受体抑制剂的用途
EP2496234A1 (de) 2009-11-07 2012-09-12 Merck Patent GmbH Heteroarylaminochinoline als tgf-beta-rezeptorkinase-inhibitoren
BR112012018954A2 (pt) * 2010-02-05 2016-04-12 Merck Patent Gmbh derivados de hetaril-[1,8]naftiridina
TW201210597A (en) * 2010-06-09 2012-03-16 Gilead Sciences Inc Inhibitors of hepatitis C virus
AU2011273931B2 (en) * 2010-06-28 2015-04-23 Merck Patent Gmbh 2,4- diaryl - substituted [1,8] naphthyridines as kinase inhibitors for use against cancer
ES2542647T3 (es) * 2011-03-09 2015-08-07 Merck Patent Gmbh Derivados de pirido[2,3 b]pirazina y sus usos terapéuticos
US20150275306A1 (en) 2012-10-10 2015-10-01 Stichting Het Nederlands Kanker Instituut Antoni van Leeuwenhoek Ziekenhuis Methods and means for predicting resistance to anti-cancer treatment
PL2970890T3 (pl) 2013-03-14 2020-11-16 The Brigham And Women's Hospital, Inc. Kompozycje i sposoby ekspansji i hodowli nabłonkowych komórek macierzystych
KR101658111B1 (ko) * 2013-05-13 2016-09-20 제일모직 주식회사 유기광전자소자용 화합물, 이를 포함하는 유기발광소자 및 상기 유기발광소자를 포함하는 표시장치
CN103570632B (zh) * 2013-07-22 2015-09-30 成都理工大学 无催化剂的4(3h)-喹唑啉酮的合成方法
PL3089971T3 (pl) 2014-01-01 2021-01-25 Medivation Technologies Llc Związki i sposoby ich zastosowania
EP3189134A1 (de) 2014-09-03 2017-07-12 The Brigham and Women's Hospital, Inc. Zusammensetzungen, systeme und verfahren zur erzeugung von innenohrhaarzellen zur behandlung von gehörverlust
US10626094B2 (en) 2014-10-14 2020-04-21 Sanford Burnham Prebys Medical Discovery Institute Inhibitors of low molecular weight protein tyrosine phosphatase and uses thereof
US10669528B2 (en) 2015-06-25 2020-06-02 Children's Medical Center Corporation Methods and compositions relating to hematopoietic stem cell expansion, enrichment, and maintenance
US10399987B2 (en) 2015-07-28 2019-09-03 Bristol-Myer Squibb Company TGF beta receptor antagonists
US11021687B2 (en) 2016-01-08 2021-06-01 The Brigham And Women's Hospital, Inc. Production of differentiated enteroendocrine cells and insulin producing cells
US11583593B2 (en) 2016-01-14 2023-02-21 Synthis Therapeutics, Inc. Antibody-ALK5 inhibitor conjugates and their uses
US10213511B2 (en) 2016-03-02 2019-02-26 Frequency Therapeutics, Inc. Thermoreversible compositions for administration of therapeutic agents
US11260130B2 (en) 2016-03-02 2022-03-01 Frequency Therapeutics, Inc. Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using a GSK3 inhibitor: IV
US10201540B2 (en) 2016-03-02 2019-02-12 Frequency Therapeutics, Inc. Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using GSK3 inhibitors: I
EP4049665B1 (de) 2016-03-15 2025-03-12 The Children's Medical Center Corporation Verfahren und zusammensetzungen im zusammenhang mit der expansion hämatopoetischer stammzellen
EP3562827A1 (de) 2016-12-30 2019-11-06 Frequency Therapeutics, Inc. 1h-pyrrol-2,5-dion-verbindungen und verfahren zur verwendung davon zur induktion der selbsterneuerung von unterstützenden stamm-/vorläuferzellen
WO2018204176A1 (en) 2017-05-01 2018-11-08 Sanford Burnham Prebys Medical Discovery Institute Inhibitors of low molecular weight protein tyrosine phosphatase (lmptp) and uses thereof
CN109096254B (zh) * 2017-06-20 2021-07-06 江西师范大学 喹唑啉衍生物及其制备方法和应用
CN112135613A (zh) 2018-03-20 2020-12-25 西奈山伊坎医学院 激酶抑制剂化合物和组合物及使用方法
US20210254006A1 (en) 2018-06-06 2021-08-19 Ideaya Biosciences, Inc. Methods of culturing and/or expanding stem cells and/or lineage committed progenitor cells using lactam compounds
US11617745B2 (en) 2018-08-17 2023-04-04 Frequency Therapeutics, Inc. Compositions and methods for generating hair cells by downregulating FOXO
JP2021533788A (ja) 2018-08-17 2021-12-09 フリークエンシー セラピューティクス インコーポレイテッド Ｊａｇ−１を上方制御することにより有毛細胞を生成するための組成物及び方法
WO2020142485A1 (en) 2018-12-31 2020-07-09 Icahn School Of Medicine At Mount Sinai Kinase inhibitor compounds and compositions and methods of use
EP4681774A3 (de) 2021-03-29 2026-03-25 Gilead Sciences, Inc. Khk-hemmer

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5776963A (en) * 1989-05-19 1998-07-07 Hoechst Marion Roussel, Inc. 3-(heteroaryl)-1- (2,3-dihydro-1h-isoindol-2-yl)alkyl!pyrrolidines and 3-(heteroaryl)-1- (2,3-dihydro-1h-indol-1-yl)alkyl!pyrrolidines and related compounds and their therapeutic untility
US5223501A (en) * 1991-05-10 1993-06-29 Merck & Co., Inc. Substituted pyrimidinones bearing acidic functional groups as angiotensin ii antagonists
US6225318B1 (en) * 1996-10-17 2001-05-01 Pfizer Inc 4-aminoquinazolone derivatives
US6184226B1 (en) * 1998-08-28 2001-02-06 Scios Inc. Quinazoline derivatives as inhibitors of P-38 α
AU2003229305A1 (en) 2002-05-17 2003-12-02 Scios, Inc. TREATMENT OF FIBROPROLIFERATIVE DISORDERS USING TGF-Beta INHIBITORS
EP1575506A4 (de) 2002-07-25 2008-04-23 Scios Inc Verfahren zur verbesserung der lungenfunktion mit tgf-beta hemmern

Also Published As

Publication number Publication date
US20040204431A1 (en) 2004-10-14
ES2305744T3 (es) 2008-11-01
US8268857B2 (en) 2012-09-18
WO2004081009A1 (en) 2004-09-23
EP1603908A1 (de) 2005-12-14
EP1603908B1 (de) 2008-06-11
US20070142408A1 (en) 2007-06-21
DE602004014347D1 (de) 2008-07-24
US7189733B2 (en) 2007-03-13

Similar Documents

Publication Publication Date Title
ATE398125T1 (de) Chinazolin-derivate als tgf-beta-inhibitoren
UA87153C2 (ru) Энантиомерно чистые аминогетероарильные соединения как ингибиторы протеинкиназы
DK1767535T3 (da) Syntese af epothiloner, mellemprodukter deraf, analoge og deres anvendelse
ATE433447T1 (de) Pyrimiidinverbindungen
EA200600317A1 (ru) Производные омега-карбоксиарилдифенилмочевины (варианты), фармацевтическая композиция (варианты) и способ лечения и предупреждения заболеваний и состояний с их использованием (варианты)
CY1119077T1 (el) Παραγωγα πυραζολυλαμινοπυριδινης χρησιμα ως αναστολεις κινασων
NO20032801L (no) Tiazolderivater for behandling av PPAR-relaterte forstyrrelser
SE0301373D0 (sv) Novel compounds
ATE302775T1 (de) Carbolinderivate
ATE461188T1 (de) Verstärker von glutamat-rezeptoren
CY1107403T1 (el) Μια μεθοδος δια την παρασκευη υπερινδοπριλης,των αναλογων ενωσεων αυτης και των αλατων αυτων με χρησιμοποιηση ενδιαμεσων ενωσεων 2,5-διοξο-οξαζολιδινης
NO20044526L (no) Hemisterlinderivater og anvendelser derav
EA200700202A1 (ru) Гетероарильные соединения в качестве бетамиметиков для лечения заболеваний дыхательных путей
MA32956B1 (fr) Derives de 5-amino-2-(1-hydroxyethyl)-tetrahydropyrane
NO20043016L (no) 6-aminomorfinan-derivater, fremgangsmate for fremstilling og anvendelse derav
ES2186550B2 (es) Nuevos derivados de oxazolidinonas como antibacterianos.
EA200501584A1 (ru) Бета-карболины, применяемые для лечения воспалительных заболеваний
ATE399168T1 (de) Imidazopyridin-derivate und ihre verwendung als induzierbare no-synthase inhibitoren
HRP20080057T3 (en) 9,10-alpha,alpha-oh-taxane analogs and methods for production thereof
ATE441630T1 (de) Substituierte cyclopenten-verbindungen
ECSP045396A (es) Proceso para preparar derivados de 6-alquiliden penem
ATE543803T1 (de) 3-ä2-(3-azylamino-2-oxo-2h-pyridin-1- yl)acetylaminoü-4-oxopentansäurederivate und deren verwendung als caspase-inhibitoren
DE602005011267D1 (de) Benzofuran- und benzothiophenderivate, die sich für die behandlung von herzkreislauferkrankungen eignen
CO5540311A2 (es) Derivados de pirimidina utiles como inhibidores de cox-2 selectivos
EA200600608A1 (ru) Производные имидазопиридина как ингибиторы индуцируемой no-синтазы

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties